APVO - Aptevo Therapeutics Inc Stock Price, Fair Value and News

0.73USD-0.02 (-2.67%)Delayed as of 30 Apr 2024, 11:42 am ET

Market Summary

USD0.73-0.02

Delayedas of 30 Apr 2024, 11:42 am

-2.67%

APVO Stock Price

View Fullscreen

APVO RSI Chart

APVO Valuation

Market Cap

400.1K

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

0.12

EV/EBITDA

0.91

Price/Free Cashflow

-0.03

APVO Price/Sales (Trailing)

APVO Profitability

EBT Margin

-598.91%

Return on Equity

-142.47%

Return on Assets

-70.09%

Free Cashflow Yield

-2.9K%

APVO Fundamentals

APVO Revenue

Revenue (TTM)

3.1M

APVO Earnings

Earnings (TTM)

-17.4M

Earnings Growth (Yr)

-27.15%

Earnings Growth (Qtr)

6.81%

Breaking Down APVO Revenue

52 Week Range

0.75

(Low)(High)

Last 7 days

5.6%

Last 30 days

-84.0%

Last 90 days

-89.2%

Trailing 12 Months

-99.1%

How does APVO drawdown profile look like?

APVO Financial Health

Current Ratio

2.64

Debt/Equity

0.12

Debt/Cashflow

-8.06

APVO Investor Care

Shares Dilution (1Y)

245.99%

Diluted EPS (TTM)

-63.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	13.0M	37.7M	20.4M	3.1M
2021	6.8M	9.4M	11.0M	12.3M
2020	0	23.1M	13.7M	4.3M
2019	26.0M	26.6M	29.7M	32.4M
2018	16.6M	19.9M	19.5M	23.1M
2017	23.9M	17.3M	20.6M	14.7M
2016	30.0M	33.1M	29.4M	29.8M
2015	0	0	0	33.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aptevo Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	taylor daphne	acquired	-	-	1,584	svp, cfo
Mar 03, 2024	white marvin l	acquired	-	-	9,584	president and ceo
Mar 03, 2024	lamothe jeffrey g.	acquired	-	-	3,667	evp, coo
Mar 03, 2024	kwon soyoung	acquired	-	-	3,667	svp, gc, bd & corp affairs
Mar 02, 2024	taylor daphne	acquired	-	-	3,667	svp, cfo
Mar 02, 2024	white marvin l	acquired	-	-	12,917	president and ceo
Mar 02, 2024	lamothe jeffrey g.	acquired	-	-	5,500	evp, coo
Mar 02, 2024	kwon soyoung	acquired	-	-	3,667	svp, gc, bd & corp affairs
Jan 29, 2024	taylor daphne	acquired	-	-	792	svp, cfo
Jan 28, 2024	white marvin l	acquired	-	-	4,792	president and ceo

Which funds bought or sold APVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	sold off	-100	-4.00	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	sold off	-100	-53.00	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	new	-	28.00	28.00	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-21.00	26.00	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-58.51	-56,349	16,602	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-16,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	47,444	47,444	-%
Feb 14, 2024	CANTOR FITZGERALD, L. P.	added	3.86	-8,003	10,594	-%
Feb 14, 2024	EARNEST PARTNERS LLC	sold off	-100	-5.00	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	18,934	18,934	-%

Are Funds Buying or Selling APVO?

Are funds buying APVO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APVO

No. of Funds

Unveiling Aptevo Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	1,731,034	SC 13G
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Nov 26, 2021	tang capital partners lp	0.0%	0	SC 13D/A
Nov 22, 2021	tang capital partners lp	18.8%	921,336	SC 13D/A
Jun 21, 2021	tang capital partners lp	39.6%	1,760,000	SC 13D/A
Feb 16, 2021	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 16, 2021	armistice capital, llc	0%	0	SC 13G/A
Feb 12, 2021	rtw investments, lp	6.96%	288,236	SC 13G/A
Feb 12, 2021	stonepine capital management, llc	0.4%	18,280	SC 13G/A
Feb 11, 2021	renaissance technologies llc	5.81%	254,423	SC 13G/A

Recent SEC filings of Aptevo Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 15, 2024	8-K	Current Report
Apr 12, 2024	424B4	Prospectus Filed
Apr 10, 2024	EFFECT	EFFECT
Apr 09, 2024	S-1/A	Initial Public Offering
Mar 29, 2024	S-1/A	Initial Public Offering
Mar 20, 2024	S-1	Initial Public Offering
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Aptevo Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Aptevo Therapeutics Inc News

Latest updates

Aptevo Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-	-	-	-	27,861,000	3,114,000	3,665,000	3,096,000	3,110,000	2,421,000	2,373,000	1,463,000	5,247,000	9,031,000	9,011,000	7,360,000	7,022,000	6,346,000	5,824,000	6,826,000	4,071,000	2,818,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	7,280,000	-	-	10,404,000	11,162,000	-	-	-	-	-
S&GA Expenses	-7.2%	2,793,000	3,010,000	3,307,000	3,697,000	3,859,000	3,162,000	3,479,000	4,110,000	3,947,000	4,280,000	3,215,000	2,840,000	3,528,500	3,863,000	4,279,000	4,528,000	6,577,500	6,940,000	7,023,000	7,592,000	-
R&D Expenses	-23.2%	3,590,500	4,674,000	4,477,000	3,865,000	4,866,000	4,543,000	4,367,000	4,722,000	5,362,000	4,912,000	4,494,000	4,440,000	4,408,000	7,596,000	6,125,000	6,634,000	8,899,000	8,574,000	9,713,000	8,199,000	-
EBITDA Margin	-328.5%	-5.81	2.54	-2.49	-1.35	-3.91	-4.13	-4.61	-5.41	-7.41	-11.72	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-999,000	-	-	-	-	-	-	-7,714,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-6,948,000	-	-	-12,084,000	-	-	-14,096,000	-12,562,000	-13,155,000	-13,908,000	-17,409,000
EBT Margin	-365.9%	-5.99	2.25	-2.54	-1.38	-4.00	-4.22	-4.72	-5.54	-7.59	-12.04	-	-	-	-	-	-	-	-	-	-	-
Net Income	-27.2%	-5,902,500	-4,642,000	-7,644,000	28,010,000	-7,697,000	-6,272,000	-6,997,000	-7,932,000	-7,256,000	-7,053,000	-6,791,000	-6,803,000	-8,174,000	-6,924,000	-13,332,000	-12,018,000	-14,128,500	-12,562,000	-13,144,000	-13,854,000	-
Net Income Margin	-316.9%	-5.59	2.58	0.31	0.19	-2.23	-2.32	-2.66	-3.10	-4.08	-4.12	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	11.6%	-5,253,000	-5,939,000	-6,900,000	-3,188,000	-5,235,000	-3,998,000	-5,255,000	-5,444,000	-7,695,000	-6,123,000	-7,387,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.4%	25.00	27.00	29.00	35.00	34.00	32.00	39.00	45.00	57.00	64.00	71.00	69.00	54.00	37.00	19.00	25.00	53.00	61.00	66.00	81.00	67.00
Current Assets	-9.8%	19.00	21.00	23.00	28.00	27.00	25.00	31.00	42.00	53.00	59.00	66.00	63.00	47.00	31.00	10.00	15.00	30.00	37.00	44.00	58.00	49.00
Cash Equivalents	-11.5%	17.00	19.00	21.00	25.00	23.00	22.00	29.00	35.00	45.00	52.00	60.00	58.00	40.00	25.00	8.00	12.00	12.00	18.00	21.00	37.00	31.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	7.00	7.00	4.00	2.00
Net PPE	-11.5%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00
Liabilities	1.7%	13.00	12.00	13.00	12.00	16.00	16.00	16.00	51.00	55.00	57.00	58.00	58.00	37.00	35.00	10.00	10.00	42.00	41.00	40.00	42.00	37.00
Current Liabilities	5.7%	7.00	7.00	7.00	6.00	9.00	8.00	7.00	24.00	35.00	32.00	31.00	29.00	15.00	7.00	7.00	7.00	38.00	37.00	17.00	18.00	18.00
Long Term Debt	-	-	-	-	-	1.00	2.00	-	-	4.00	-	-	-	-	-	-	-	-	-	20.00	19.00	19.00
LT Debt, Current	-	-	-	-	-	2.00	2.00	2.00	2.00	12.00	11.00	11.00	10.00	5.00	-	-	-	20.00	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	1.00	2.00	-	-	4.00	-	-	-	-	-	-	-	-	-	20.00	19.00	19.00
Shareholder's Equity	-17.0%	12.00	15.00	16.00	23.00	18.00	16.00	23.00	-	1.00	7.00	14.00	11.00	17.00	2.00	9.00	15.00	12.00	20.00	26.00	39.00	30.00
Retained Earnings	-2.7%	-223	-217	-211	-203	-206	-201	-193	-221	-214	-207	-200	-192	-185	-178	-171	-164	-167	-159	-152	-139	-127
Additional Paid-In Capital	1.5%	236	232	227	226	224	217	217	216	215	215	215	203	202	181	180	180	180	179	179	179	158
Shares Outstanding	34.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Float	-	-	-	11.00	-	-	-	18.00	-	-	-	93.00	-	-	-	24.00	-	-	-	37.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	15.8%	-5,253	-6,240	-4,803	4,566	-5,939	-6,896	-3,070	-5,117	-3,880	-5,242	-5,053	-7,504	-6,123	-7,387	-4,633	-11,175	-5,100	-7,548	-15,891	-13,844	-7,292
Share Based Compensation	-21.3%	358	455	465	915	357	359	485	601	178	319	572	574	198	343	301	413	269	334	401	594	493
Cashflow From Investing	-	-	-	-	-	-	-4.00	-	-	-118	-13.00	-391	-191	-88.00	-	-	28,120	-	4,250	-	-153	9,041
Cashflow From Financing	-29.9%	3,046	4,344	481	-1,873	5,998	-500	-3,178	-4,936	-3,076	-3,021	8,316	23,942	21,248	24,730	-	-22,104	-135	24.00	-113	20,373	39.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APVO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Royalty revenue		$ 3,114
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember
Operating expenses:
Research and development	$ (17,107)	$ (17,882)
General and administrative	(11,771)	(13,873)
Loss from operations	(28,878)	(28,641)
Other income (expense):
Other income (expense) from continuing operations, net	578	(4,027)
Gain related to sale of non-financial asset	9,650
Gain on extinguishment of liability related to sale of royalties		37,182
Milestone income related to sale of royalties		2,500
Net (loss) income from continuing operations	(18,650)	7,014
Discontinued operations:
Income from discontinued operations	1,239	1,013
Net (loss) income	$ (17,411)	$ 8,027
Net (loss) income per share:
Basic	$ (1.42)	$ 1.57
Diluted	$ (1.42)	$ 1.57
Shares used in calculation:
Basic	12,234,661	5,100,310
Diluted	12,234,661	5,102,914

APVO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 16,904	$ 22,635
Royalty and milestone receivable		2,500
Prepaid expenses	1,473	1,571
Other current assets	689	744
Total current assets	19,066	27,450
Property and equipment, net	895	1,462
Operating lease right-of-use asset	4,881	5,303
Total assets	24,842	34,215
Current liabilities:
Accounts payable and other accrued liabilities	3,984	3,499
Accrued compensation	2,098	2,105
Current portion of long-term debt		2,000
Other current liabilities	1,142	1,102
Total current liabilities	7,224	8,706
Long-term debt		1,456
Operating lease liability	5,397	6,079
Total liabilities	12,621	16,241
Stockholders' equity:
Common stock: $0.001 par value; 500,000,000 shares authorized; 19,468,180 and 6,466,294 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	61	48
Additional paid-in capital	235,607	223,962
Accumulated deficit	(223,447)	(206,036)
Total stockholders' equity	12,221	17,974
Total liabilities and stockholders' equity	$ 24,842	$ 34,215

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

CEO	Mr. Marvin L. White
WEBSITE	aptevotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Aptevo Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aptevo Therapeutics Inc? What does APVO stand for in stocks?

APVO is the stock ticker symbol of Aptevo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptevo Therapeutics Inc (APVO)?

As of Mon Apr 29 2024, market cap of Aptevo Therapeutics Inc is 400.1 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers. The fair value of Aptevo Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptevo Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptevo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APVO is over valued or under valued. Whether Aptevo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aptevo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APVO.

What is Aptevo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, APVO's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 0.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APVO PE ratio will change depending on the future growth rate expectations of investors.